ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF

BeOne Medicines Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$370.17+1.11 (+0.30%)

Close on Oct 19, 2026

Market cap: $557.24B
P/E (TTM): 860.9
Dividend yield: –

BeOne Medicines Ltd. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	5,343	3,810	2,459	1,416	1,176	309	428	198	238	1.07	8.82	13
Cost of Revenue	–	–	–	286	165	71	71	29	4.97	0	–	–
Gross Profit	4,674	3,216	2,079	1,129	1,011	238	357	170	233	1.07	–	–
Research & Development	2,146	1,953	1,779	1,641	1,459	1,295	927	679	269	98	58	22
Selling, General & Admin	2,081	1,831	1,508	1,279	990	600	388	195	63	20	7.31	–
General & Administrative	–	–	–	–	–	–	–	–	–	20	7.31	6.93
Total Costs & Expenses	4,227	3,784	3,287	2,919	2,450	1,967	1,388	904	337	118	66	29
Operating Income	447	-568	-1,208	-1,790	-1,439	-1,658	-960	-706	-98	-117	-57	-16
Interest Expense	58	22	4.36	22	29	18	15	13	–	–	–	–
Interest & Investment Income	71	70	78	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	-16	-22	7.63	12	0	0	–	–	–	–
Other Non-Operating Income	-43	-13	308	-224	16	37	7.17	1.99	12	-0.97	1.22	0.60
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0
Gain (Loss) on Investments	-0.60	-17	-8.69	–	–	–	–	1.95	0.04	-1.42	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	-0.13	-0.09	0	-0.01	-0.05
Legal Settlements	0	0	363	0	0	–	–	–	–	–	–	–
Pretax Income	417	-533	-826	-1,961	-1,439	-1,618	-944	-690	-91	-119	-57	-19
Income Tax Expense	130	112	56	43	19	10	6.99	-16	2.24	0.05	0	0
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	-119	-57	-19
Net Income incl. Noncontrolling Interests	–	–	-882	-2,004	-1,458	-1,629	-951	-674	-93	-119	-57	-19
Minority Interest in Earnings	–	–	–	0	0	-3.62	-1.95	-0.26	-0.19	0	–	-0.27
Net Income	287	-645	-882	-2,004	-1,458	-1,625	-949	-674	-93	-119	-57	-18
Net Income to Common	–	–	–	–	–	–	–	–	-93	-119	-57	-18
EPS (Basic)(per share)	0.20	-0.47	-0.65	-1.49	-1.21	-1.50	-1.22	-0.93	-0.17	-0.30	-0.52	-0.18
EPS (Diluted)(per share)	0.19	-0.47	-0.65	-1.49	-1.21	-1.50	-1.22	-0.93	-0.17	-0.30	-0.52	-0.18
Shares Outstanding (Basic, Weighted)(shares)	1,418	1,369	1,357	1,341	1,206	1,085	781	721	543	404	111	100
Shares Outstanding (Diluted, Weighted)(shares)	1,475	1,369	1,357	1,341	1,206	1,085	781	721	543	404	111	100
EBITDA	589	-396	-1,120	-1,723	-1,392	-1,626	-941	-695	-94	-115	-55	–
Net Interest Income	–	–	74	52	-16	2.00	9.13	14	-4.11	0.38	0.56	-3.51

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 88.9%
Operating margin: 15.1%
Net margin: 10.7%
Return on equity, FY2025: 7.5%

Financial strength

Current ratio: 3.40
Debt to equity: 0.22
Debt to assets: 12.5%
Cash to current liabilities: 240.6%

Valuation

P/E ratio: 860.9
Price to sales: 90.92
Price to book: 107.70
Dividend yield: –